Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
12 participants
INTERVENTIONAL
2006-10-31
2007-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Atorvastatin
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* C-reactive protein level \> 2 mg/L in absence of an infection
* Fecal calprotectin \> 250 mg/kg or CDAI \> 150
Exclusion Criteria
* Prednisolone dosage above 15 mg/day
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Skane University Hospital
OTHER
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Olof Grip, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Malmo University Hospital, Region Skåne
Anders Bredberg, MD, PhD
Role: STUDY_CHAIR
Malmo University Hospital, Region Skåne
Gunnel Bredberg, MD, PhD
Role: STUDY_CHAIR
Malmo University Hospital, Region Skåne
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of Medicine, Division of Gastroenterology and Hepatology
Malmo, , Sweden
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Grip O, Janciauskiene S. Atorvastatin reduces plasma levels of chemokine (CXCL10) in patients with Crohn's disease. PLoS One. 2009;4(5):e5263. doi: 10.1371/journal.pone.0005263. Epub 2009 May 6.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
010-02
Identifier Type: -
Identifier Source: org_study_id